Tong Ren Tang Technologies Co stock analysis
Tong Ren Tang Technologies Co (TGRNF) Stock Price & Analysis
TGRNF Stock Chart & Stats
- Day’s Range
- $0.37 - $0.37
- 52-Week Range
- $0.36 - $0.67
- Previous Close
- $0.37
- Volume
- N/A
- Average Volume (3M)
- 114
- Market Cap
- $487.28M
- Enterprise Value
- $3.91B
- Total Cash (Recent Filing)
- $5.00B
- Total Debt (Recent Filing)
- $1.91B
- Price to Earnings (P/E)
- 10.8
- Beta
- 0.57
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 18, 2026
- Dividend Yield
- 7.18%
Bulls Say, Bears Say
Bulls Say
Improving Balance Sheet
Moderate and improving leverage reduces balance-sheet risk and preserves financial flexibility. Steadily growing equity provides a stronger capital base, helping the company absorb weaker operating periods and continue funding its healthcare business without excessive reliance on debt.
Strong 2025 Cash Rebound
The sharp 2025 recovery in operating and free cash flow demonstrates that the business can generate substantial internal funding when cash conversion improves. This supports reinvestment, dividends, and balance-sheet resilience over the coming quarters, despite prior volatility.
Positive Operating Profitability
Despite weaker sales and compressed margins, the company remained meaningfully profitable at the operating and EBITDA levels. These positive margins indicate an established commercial model and provide a base from which management can rebuild growth and protect cash generation.
Bears Say
Revenue Contraction
The shift from several years of growth to a 9.1% revenue decline signals weakening demand or execution momentum in the core business. If sustained, lower sales would reduce operating leverage, limit reinvestment capacity, and make a near-term earnings recovery more difficult.
Margin And Earnings Pressure
Lower gross and net margins, combined with the fall in net income from approximately 522m to 386m, show that profitability weakened materially. Continued pressure would reduce earnings resilience and constrain the company’s ability to convert its established brand and distribution into shareholder returns.
Volatile Cash Conversion
The contrast between very weak 2024 cash generation and strong 2025 recovery indicates inconsistent cash conversion across periods. Such volatility can complicate planning, dividend support, and investment decisions, particularly if working-capital swings recur during another operating slowdown.
Tong Ren Tang Technologies Co News
TGRNF FAQ
What was Tong Ren Tang Technologies Co’s price range in the past 12 months?
What is Tong Ren Tang Technologies Co’s market cap?
When is Tong Ren Tang Technologies Co’s upcoming earnings report date?
How were Tong Ren Tang Technologies Co’s earnings last quarter?
Is Tong Ren Tang Technologies Co overvalued?
Does Tong Ren Tang Technologies Co pay dividends?
What is Tong Ren Tang Technologies Co’s EPS estimate?
How many shares outstanding does Tong Ren Tang Technologies Co have?
What happened to Tong Ren Tang Technologies Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tong Ren Tang Technologies Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tong Ren Tang Technologies Co
Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of traditional Chinese medicine products. The company's involvement is comprehensive, extending to the cultivation, sourcing, and distribution of Chinese medicinal raw materials. Beyond its core offerings, Tong Ren Tang diversifies its product portfolio with items such as ointments, tea beverages, and specialized foot care solutions. The enterprise is also active in the technological advancement and commercialization of biological products, alongside Western pharmaceuticals, cosmetics, and general healthcare goods. Its distribution network includes both wholesale and retail channels for Chinese medicines and health-related products. Furthermore, Tong Ren Tang provides a broad spectrum of services, including medical research and development, Chinese medical consultation and treatment, advertising, internal and external surgical procedures, medical examinations, and hospital management. Additionally, the company engages in the processing of biochemical products, plant extraction, and the production of various food and daily chemical items.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Chun You Zhang
- Employees
- 3,801
- Website
- www.tongrentangkj.com
- Address
- No. 20 Nansanhuan Zhonglu Road, Beijing, BE, 100079, CN
Tong Ren Tang Technologies Co (TGRNF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 2 | 0 | 10 |











